Mark Boyd
Cited by
Cited by
Prespecified dose-response analysis for a very early rehabilitation trial (AVERT)
J Bernhardt, L Churilov, F Ellery, J Collier, J Chamberlain, P Langhorne, ...
Neurology 86 (23), 2138-2145, 2016
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort
WP Law, CJ Duncombe, A Mahanontharit, MA Boyd, K Ruxrungtham, ...
Aids 18 (8), 1169-1177, 2004
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection …
CDA Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A ...
The Lancet 381 (9883), 2091-9, 2013
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001
WP Law, GJ Dore, CJ Duncombe, A Mahanontharit, MA Boyd, ...
Aids 17 (15), 2191-2199, 2003
Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps
MA Boyd, M Boffito, A Castagna, V Estrada
HIV medicine 20, 3-11, 2019
Long-term survival in HIV positive patients with up to 15 years of antiretroviral therapy
H McManus, CC O'Connor, M Boyd, J Broom, D Russell, K Watson, ...
PloS one 7 (11), e48839, 2012
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis
MA Boyd, CL Moore, JM Molina, R Wood, JS Madero, M Wolff, ...
The lancet HIV 2 (2), e42-e51, 2015
Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir
MA Boyd, P Srasuebkul, K Ruxrungtham, PI Mackenzie, V Uchaipichat, ...
Pharmacogenetics and genomics 16 (5), 321-329, 2006
Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients
D Burger, M Boyd, C Duncombe, M Felderhof, A Mahanontharit, ...
Journal of Antimicrobial Chemotherapy 51 (5), 1231-1238, 2003
Effectiveness of protease inhibitor/nucleos (t) ide reverse transcriptase inhibitor–based second-line antiretroviral therapy for the treatment of human immunodeficiency virus …
AJ Stockdale, MJ Saunders, MA Boyd, LJ Bonnett, V Johnston, ...
Clinical infectious diseases 66 (12), 1846-1857, 2018
Improvements in antiretroviral therapy outcomes over calendar time
MA Boyd
Current Opinion in HIV and AIDS 4 (3), 194-199, 2009
Pandemic influenza: clinical issues
M Boyd, K Clezy, R Lindley, R Pearce
Medical journal of Australia 185 (S10), S44-S47, 2006
Intensification of Antiretroviral Therapy With Raltegravir or Addition of Hyperimmune Bovine Colostrum in HIV-Infected Patients With Suboptimal CD4+ T-Cell …
H Byakwaga, M Kelly, DFJ Purcell, MA French, J Amin, SR Lewin, ...
Journal of Infectious Diseases 204 (10), 1532-1540, 2011
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines
E Wright, A Grulich, K Roy, M Boyd, V Cornelisse, D Russell, D O'Donnell, ...
Journal of virus eradication 3 (3), 168-184, 2017
Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis
AC Achhra, G Mwasakifwa, J Amin, MA Boyd
The Lancet HIV 3 (8), e351-e360, 2016
Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials
D Carey, J Amin, M Boyd, K Petoumenos, S Emery
Journal of Antimicrobial Chemotherapy 65 (9), 1878-1888, 2010
Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research
MA Boyd, DA Cooper
Aids 21, S55-S63, 2007
Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients
M Boyd, P Mootsikapun, D Burger, T Chuenyam, S Ubolyam, ...
Antiviral therapy 10 (2), 301-307, 2005
Australasian society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018
E Wright, A Grulich, K Roy, M Boyd, V Cornelisse, D Russell, D O'Donnell, ...
Journal of virus eradication 4 (3), 143-159, 2018
Lack of enzyme‐inducing effect of rifampicin on the pharmacokinetics of enfuvirtide
MA Boyd, X Zhang, A Dorr, K Ruxrungtham, S Kolis, K Nieforth, ...
The Journal of Clinical Pharmacology 43 (12), 1382-1391, 2003
The system can't perform the operation now. Try again later.
Articles 1–20